Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05297045
Other study ID # RGT001-075_01-201
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date March 29, 2022
Est. completion date May 30, 2023

Study information

Verified date November 2023
Source Regor Pharmaceuticals Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 2 study designed to evaluate the efficacy of daily (QD) oral RGT001-075 GLP1 receptor agonist relative to placebo after up to 16 weeks of double-blind treatment as determined by mean change from baseline in HbA1c in adult patients with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control with diet and exercise and stable metformin treatment.


Recruitment information / eligibility

Status Terminated
Enrollment 17
Est. completion date May 30, 2023
Est. primary completion date May 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Diagnosed with type 2 diabetes that has been treated with lifestyle modification and a stable dose of metformin =1000 mg/day (or maximum tolerated dose) for at least 3 months at the time of Screening - Screening HbA1c 7.0-10.5% - Male or female, age 18-75 years - Screening BMI 24.5 - 40 kg/m2 - Either surgically sterile, abstinent, or willing to use a highly effective method of contraception for the entirety of the study, and not be pregnant or lactating if a woman of child-bearing potential Exclusion Criteria: - Has received within the preceding 3 months prior to Screening, another approved or investigational oral or injectable antidiabetic medication (including, but not limited to sulfonylureas, dipeptidyl peptidase-4 inhibitor [DPP-4i], sodium-glucose cotransport 2 inhibitors, alphaglucosidase inhibitors, meglitinides, thiazolidinediones) or insulin in addition to metformin therapy - Has active GI disease including acute or chronic pancreatitis, severe gastroparesis or chronic malabsorption, inflammatory bowel disease, symptomatic gallbladder or biliary disease, known unstable liver disease, a diagnosis of fibrotic nonalcoholic steatohepatitis (NASH), Gilbert's syndrome, or obvious clinical signs or symptoms of liver disease including chronic active hepatitis B or C, or primary biliary cirrhosis, or elevated alanine aminotransferase (ALT) levels at Screening - Has any history of myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary therapeutic intervention, transient ischemic attack, stroke, or decompensated congestive heart failure within previous 6 months prior to Screening - Has an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 - Has active proliferative diabetic retinopathy or macular edema - Has a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or medullary thyroid cancer - Has an active or untreated malignancy or has been in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for <5 years prior to screening - Has evidence of human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening - Has had a significant change in weight, defined as a gain or loss of at least 5% body weight in the 3 months prior to screening - Has been treated or plan to be treated with drugs or devices or surgery that promote weight loss within 3 months prior to screening

Study Design


Intervention

Drug:
RGT001-075
Oral GLP1 Receptor Agonist
Other:
Placebo
Placebo comparator

Locations

Country Name City State
United States Axon Clinical Research Doral Florida

Sponsors (1)

Lead Sponsor Collaborator
Regor Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in HbA1c from baseline to end of treatment in the modified intent-to-treat population up to 16 weeks
Secondary Change in fasting plasma glucose from baseline to end of treatment in the modified intent-to-treat population up to 16 weeks
Secondary Change in mean body weight (absolute and %) from baseline to end of treatment in the modified intent-to-treat population up to 16 weeks
Secondary Change in body mass index from baseline to end of treatment in the modified intent-to-treat population up to 16 weeks
Secondary Change in waist circumference from baseline to end of treatment in the modified intent-to-treat population up to 16 weeks
Secondary Change in mean blood lipids including triglycerides (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) from baseline to end of treatment in the modified intent-to-treat population up to 16 weeks
Secondary Percentages of patients achieving HbA1c <6.0%, <6.5%, and/or <7.0% up to 16 weeks
Secondary Percentages of patients achieving =5% and/or =10% greater body weight loss up to 16 weeks
Secondary Incidence of treatment-emergent adverse events (TEAE)s, serious adverse events (SAE)s, deaths, and adverse events (AE)s leading to study discontinuation up to 16 weeks
Secondary Vital signs - Systolic blood pressure (mmHg) absolute change from baseline up to 16 weeks
Secondary Vital signs - Diastolic blood pressure (mmHg) absolute change from baseline up to 16 weeks
Secondary Vital signs - Heart rate (beats/minute) absolute change from baseline up to 16 weeks
Secondary Vital signs - Body weight (kg) absolute and percent change from baseline up to 16 weeks
Secondary Safety clinical laboratories - complete blood count absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum sodium absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum potassium absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum total bilirubin absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum direct bilirubin absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum alkaline phosphatase absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum alanine aminotransferase absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum aspartate aminotransferase absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum blood urea nitrogen absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum creatinine absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum uric acid absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum calcium absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum lipase absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum amylase absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - eGFR (calculated) absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - fasting serum glucose absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum albumin absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum total protein absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - fasting serum total cholesterol absolute change from baseline up to 16 weeks
Secondary Safety clinical laboratories - fasting serum triglycerides absolute and percent change from baseline up to 16 weeks
Secondary Safety clinical laboratories - fasting serum HDL-C absolute and percent change from baseline up to 16 weeks
Secondary Safety clinical laboratories - fasting serum LDL-C absolute and percent change from baseline up to 16 weeks
Secondary Safety clinical laboratories - serum calcitonin absolute change from screening up to 16 weeks
Secondary ECG interval change from baseline absolute and categorical outliers >450ms up to 16 weeks
Secondary Proportion of patients who report AEs of Special Interest (AESI) including GI intolerability, hypoglycemia, drug hypersensitivity reactions, acute pancreatitis, thyroid C-cell hyperplasia and C-cell neoplasms, and cardiovascular (CV) events up to 16 weeks
See also
  Status Clinical Trial Phase
Completed NCT02771093 - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT02545842 - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) Phase 4
Recruiting NCT03436212 - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. N/A
Completed NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Phase 2
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Recruiting NCT06065540 - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Phase 3
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT04091373 - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide Phase 1
Completed NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Phase 1
Recruiting NCT06212778 - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Completed NCT05979519 - Fresh Carts for Mom's to Improve Food Security and Glucose Management N/A
Recruiting NCT05579314 - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Terminated NCT03684642 - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Phase 3
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Completed NCT03644134 - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns N/A
Completed NCT05295160 - Fasting-Associated Immune-metabolic Remission of Diabetes N/A
Completed NCT02836873 - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Phase 3
Completed NCT02226003 - Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017) Phase 3